Monday, July 22, 2024
29 C
Brunei Town

J&J suspends COVID-19 vaccine sales forecast

AP – Johnson & Johnson (J&J) is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as USD3.5 billion this year.

The healthcare giant said yesterday a global supply surplus and demand uncertainty prompted the move, which will not affect the company’s operational earnings per
share guidance.

J&J’s one-shot vaccine brought in USD457 million in global sales during the first quarter, with most of that coming from outside the United States (US). The vaccine brought in only USD75 million in sales in the US, or about 25 per cent less than what it rang up after debuting in last year’s first quarter.

J&J said it doesn’t intend to profit from the vaccine. But it said in January that it could bring in between USD3 billion and USD3.5 billion in sales this year, as countries continue to fight variants of the virus.

The vaccine brought in USD2.38 billion in sales last year.

Vaccine options from rival drugmakers Pfizer and Moderna have been much more commonly used so far in the US, where overall vaccine sales have slowed in recent weeks as the Omicron surge of the virus started to ease.

US regulators also said most Americans should receive the Pfizer or Moderna shots instead of J&J’s version due to a rare blood clotting problem tied to the shot.